RemeGen Co., Ltd
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China 2022-09-19 21:00
Biotech Company RemeGen Commemorates International Self-Care Day with Health Initiatives 2022-07-25 11:00
RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting 2022-05-24 10:27
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome 2022-01-26 10:52
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome 2022-01-25 09:00
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021 2021-12-15 09:35
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment 2021-12-03 13:45
1 2